Skip to content
CLINICAL TRIALS

Clinical Trials

We are focused on finding innovative solutions to unmet medical needs. We have completed enrollment in our second Phase III Study for CM-AT  in Autism, The Blüm™ Study.

Learn More blum_logo
img-bg-autism AUTISM

Autism

We’re working to bring a first-in-class Autism treatment to market. We believe this treatment has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered, and learn more about our novel approach.

Learn More autism-home
ABOUT US

About Us

Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological and other disorders. Our pipeline includes our lead drug candidate, CM-AT, for Autism, along with a number of therapies for other neurological conditions.

Learn more about how our research helps patients.

Learn More about-us-home2
img-bg-tech Technology

Technology

We are developing breakthrough technologies that shed light on key connections that factor into neurological diseases. We’ve found a critical link to the role of the pancreas in these conditions, and are approaching treatment with a revolutionary method of drug delivery.

Learn more technology-home
img-bg-story OUR STORY

Our Story

What started as one doctor’s observation has expanded into a broad array of treatments that may significantly affect neurological diseases. We have performed important research, made discoveries and are disrupting conventional thinking. Learn more about our story.

Learn More our-story-home
Pipeline

Pipeline

At Curemark, we are working towards a product pipeline that brings breakthrough medical discoveries to the patients who need them the most.

Learn More investor-relations
img-bg-contact CONTACT US

Contact Us

We put the patient first, in everything we do. Get the latest updates on our company, products, clinical trials and more.

Learn More contact-us
News

News

Browse Curemark’s latest updates, upcoming events and product news.

Learn More news-home
CLINICAL TRIALS

Clinical Trials

We are focused on finding innovative solutions to unmet medical needs. We have completed enrollment in our second Phase III Study for CM-AT  in Autism, The Blüm™ Study.

Learn More blum_logo
img-bg-autism AUTISM

Autism

We’re working to bring a first-in-class Autism treatment to market. We believe this treatment has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered, and learn more about our novel approach.

Learn More autism-home
ABOUT US

About Us

Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological and other disorders. Our pipeline includes our lead drug candidate, CM-AT, for Autism, along with a number of therapies for other neurological conditions.

Learn more about how our research helps patients.

Learn More about-us-home2
img-bg-tech Technology

Technology

We are developing breakthrough technologies that shed light on key connections that factor into neurological diseases. We’ve found a critical link to the role of the pancreas in these conditions, and are approaching treatment with a revolutionary method of drug delivery.

Learn more technology-home
img-bg-story OUR STORY

Our Story

What started as one doctor’s observation has expanded into a broad array of treatments that may significantly affect neurological diseases. We have performed important research, made discoveries and are disrupting conventional thinking. Learn more about our story.

Learn More our-story-home
Pipeline

Pipeline

At Curemark, we are working towards a product pipeline that brings breakthrough medical discoveries to the patients who need them the most.

Learn More investor-relations
img-bg-contact CONTACT US

Contact Us

We put the patient first, in everything we do. Get the latest updates on our company, products, clinical trials and more.

Learn More contact-us
News

News

Browse Curemark’s latest updates, upcoming events and product news.

Learn More news-home